This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any

announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the

basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase

any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the

"Prospectus") in its final form that is published by Tiziana Life Sciences plc in connection with the admission of the

Company's ordinary shares (the "Ordinary Shares") to listing on the standard segment of the Official List of the Financial

Conduct Authority (the "FCA") and to trading on the main market for listed securities (the "Main Market")

of London Stock Exchange plc (the "London Stock Exchange"). This announcement is not an offer to sell, or a solicitation

of an offer to acquire, securities in the United States, Australia, Canada, Japan or in any other jurisdiction.

New York, 18 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"),

a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces,

further to the announcement of 17 December 2020, that the Company has issued a prospectus in connection with its admission to

listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Official List of the Financial

Conduct Authority ("FCA") (the "Official List") and admission to trading on the main market for listed securities

(the "Main Market") of London Stock Exchange plc (the "London Stock Exchange") (together, "Admission").

times and dates set out in the expected timetable of principal events above and mentioned in this document, and in any other

document issued in connection with Admission are subject to change by the Company, in which event details of the new times and

dates will be notified to the FCA, the London Stock Exchange and, where appropriate, shareholders.

Prospectus was approved by the FCA on 18 December 2020 and is available to be viewed on the Company's website at: www.tizianalifesciences.com.

An electronic copy of the Prospectus will also be submitted to the National Storage Mechanism and will be available shortly for

inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Life Sciences plc is a company incorporated in England and Wales with company number 03508592. The Ordinary Shares are registered

with ISIN GB00BKWNZY55, SEDOL code BKWNZY5 and TIDM TILS. It is expected that Admission will become effective and that dealings

will commence at 8.00 am on 21 January 2021. Trading in the Company's shares on AIM will be cancelled simultaneously with Admission.

announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the

release of this information is Keeren Shah, Finance Director of Tiziana.

Tiziana Life Sciences

Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and

development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib,

the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally

administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)

in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory

diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis

and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin

6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of

statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts

but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.

Words such as anticipates,' expects,' intends,' plans,' believes,' seeks,' estimates,' and similar expressions are intended

to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and

unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and

could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company

cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which

reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement

relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release

publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events

occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.